Amplyx Pharmaceuticals has acquired international rights from Novartis for MAU868, a new experimental compound being developed to target a protein linked to BK viral disease, which causes life-threatening infections in patients who have undergone stem cell or kidney transplants. No financial details regarding the deal were disclosed.
Amplyx, Novartis enter licensing deal for potential antiviral drug
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.